Adverse Reactions & Pharmacovigilance

Serious Adverse Event SAE

TRCiddi Advers Olay

An adverse event that results in death, is life-threatening, requires or prolongs hospitalisation, causes persistent or significant disability, is a congenital anomaly, or is otherwise medically important.

In depth

Seriousness is defined by these outcome-based criteria (ICH E2A) and determines regulatory reporting obligations; it is distinct from severity, which describes intensity. A severe headache may not be serious, whereas a mild event that prolongs hospitalisation is. The medically important criterion covers events that may jeopardise the patient or require intervention to prevent one of the listed outcomes, such as allergic bronchospasm treated in an emergency department.

In clinical trials, SAEs are reported to the sponsor on an expedited basis and, when also suspected and unexpected (SUSARs), to regulators and ethics committees. In post-marketing pharmacovigilance, serious adverse reactions are likewise reported on an expedited basis to the competent authority, which in Turkey is TİTCK through TÜFAM.

Clinical pearl

Severe and serious are not synonyms: severity grades intensity, whereas seriousness is defined by outcome and triggers expedited reporting obligations.

TRIn Turkish

Ciddi Advers Olay

Ölümle sonuçlanan, yaşamı tehdit eden, hastaneye yatışı gerektiren veya uzatan, kalıcı ya da belirgin sakatlığa yol açan, konjenital anomaliye neden olan veya tıbbi açıdan önemli kabul edilen advers olaydır.

Ciddiyet bu sonuç temelli ölçütlerle (ICH E2A) tanımlanır ve düzenleyici bildirim yükümlülüklerini belirler; olayın yoğunluğunu tanımlayan şiddetten farklıdır. Şiddetli bir baş ağrısı ciddi olmayabilirken hastanede kalış süresini uzatan hafif bir olay ciddi sayılır. Tıbbi açıdan önemli olay ölçütü, hastayı tehlikeye atabilecek veya sayılan sonuçlardan birini önlemek için müdahale gerektirebilecek olayları, örneğin acil serviste tedavi edilen alerjik bronkospazmı kapsar.

Klinik araştırmalarda ciddi advers olaylar sponsora hızlandırılmış olarak bildirilir; şüpheli ve beklenmeyen nitelikte olanlar (SUSAR) ayrıca düzenleyici otoriteye ve etik kurullara bildirilir. Pazarlama sonrası farmakovijilansta da ciddi advers reaksiyonlar yetkili otoriteye, Türkiye'de TİTCK bünyesindeki TÜFAM'a, hızlandırılmış olarak bildirilir.

Şiddetli ve ciddi eş anlamlı değildir: şiddet olayın yoğunluğunu derecelendirir, ciddiyet ise sonuca göre tanımlanır ve hızlandırılmış bildirim yükümlülüğü doğurur.

Diğer adları:Ciddi istenmeyen olay
Updated 24.09.2026 0 views Educational reference — verify against current sources before clinical use.

Read next

Adverse EventAdvers Olay

Any untoward medical occurrence in a patient or clinical-trial subject given a medicinal product, whether or not it is considered causally related to the treatment.

 Adverse Drug ReactionAdvers İlaç Reaksiyonu

A noxious and unintended response to a medicinal product in which a causal relationship with the drug is at least a reasonable possibility.

 PharmacovigilanceFarmakovijilans

The science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problem (WHO definition).

 Good Clinical Practiceİyi Klinik Uygulamalar

An international ethical and scientific quality standard for designing, conducting, recording and reporting clinical trials, ensuring that participants' rights, safety and well-being are protected and that trial data are credible.

 Spontaneous ReportingSpontan Bildirim

The unsolicited submission of reports of suspected adverse drug reactions, mainly by healthcare professionals and patients, to a national pharmacovigilance centre or to the marketing authorisation holder.

 Boxed WarningKutu İçi Uyarı

A warning displayed in a bordered box at the top of US prescribing information to highlight serious or life-threatening risks, or measures essential to reduce them.